



*Società
Medico Chirurgica
di Ferrara*

dal 1846

insieme a



Università
degli Studi
di Ferrara

**Vivere, diagnosticare
e trattare la malattia
di Addison: dalla
storia ai nostri giorni**

Inquadramento clinico

Maria Chiara Zatelli

SEZIONE DI ENDOCRINOLOGIA E MEDICINA INTERNA
DIPARTIMENTO DI SCIENZE MEDICHE
UNIVERSITÀ DEGLI STUDI DI FERRARA




Ordine dei
Medici Chirurghi
e degli Odontoiatri
della provincia di
FERRARA














SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA
Azienda Ospedaliero - Universitaria di Ferrara




INQUADRAMENTO CLINICO



MALATTIA DI ADDISON

<p>Insufficient production of steroid hormones by adrenal glands</p> 	<p>Also known as primary adrenal insufficiency</p> 	<p>First described by Thomas Addison in 1885</p> 	<p>Affects about 1 per 10,000 people</p> 
<p>Occurs most frequently in middle-aged females</p> 	<p>High risk with certain medications, sepsis, & adrenal injury</p> 	<p>Causes include autoimmune adrenal destruction & tuberculosis</p> 	<p>Symptoms include abdominal pain, weakness, & weight loss</p> 
<p>Diagnosed by blood tests, urine tests, & medical imaging</p> 	<p>Treatment involves hormonal replacement</p> 	<p>Adrenal crisis (low BP, vomiting, & loss of consciousness) is serious complication</p> 	



MALATTIA DI ADDISON

Insufficienza surrenalica primitiva

SPECIAL FEATURE


Clinical Practice Guideline

Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline

«PAI is defined by the inability of the adrenal cortex to produce sufficient amounts of glucocorticoids and/or mineralocorticoids. PAI is a severe and potentially life-threatening condition due to the central role of these hormones in energy, salt, and fluid homeostasis»



INQUADRAMENTO CLINICO



MALATTIA DI ADDISON


Insufficienza surrenalica primitiva

Malattia rara
prevalenza ~ 100–140 casi/milione di abitanti e in
aumento

pregressa sottostima

miglioramento diagnostico


Prevalenza: numero di pazienti per milione



Bensing et al Eur J Endocrinol 2016

EFE 2019





MALATTIA DI ADDISON

Insufficienza surrenalica primitiva

In precedenza...

Tubercolosi	50%
Neoplasie/metastasi	30%
Emorragie	10%



Addison T. On the Constitutional and Local Effects of Disease of the Supra-renal Capsules. London, UK: Samuel Highley; 1855


...ma ai giorni nostri

Adrenalite autoimmune	80%
Tubercolosi	} 10%
Neoplasie/metastasi	
Surrenectomia	} 10%
Malattie genetiche	
Emorragie	

Erichsen et al. Eur J Endocrinol 2009; 160: 233–237
Laureti et al. J Clin Endocrinol Metab 1999; 84: 1762

Arlt et al. Lancet 2003; 361: 1881–1893
Bornstein et al. N Engl J Med 2009; 360: 2328–2339
Betterle et al. Endocr Dev 2011; 20: 161–172





MALATTIA DI ADDISON


Insufficienza surrenalica primitiva

The Adrenal Gland: Central Relay in Health and Disease

18th Adrenal Cortex Conference, 2018 Munich


► **Table 1** Incidence and prevalence of adrenal diseases in Europe.

	Annual incidence	Prevalence	Morbidity	Mortality
Congenital adrenal hyperplasia	1:10.000–1:15.000		5.8 crises per 100 patient-years; salt wasting: 8.8; simple virilising: 2.5	The HR of dying 2.3 (95% CI, 1.2–4.3) in CAH males and 3.5 (95% CI, 2.0–6.0) in CAH females compared with controls
Addison's disease	4.5/1000.000	82–144/ 1000.000	6–8 adrenal crisis/ 100 patients/year	0.5 deaths/100 patient-years from adrenal crisis
Primary aldosteronism	n.k.	4–6% of hypertensive population	OR for stroke: 4.2; OR for MI: 6.5; OR for AF: 12.1 compared to EH	2 times increased for treated PA (IAH)
Cushing disease	1–3/1000.000	66/1000.000		SMR for all-cause mortality in treated CD: 1.61
Incidentally detected adrenal mass	n.k.	1–2% of general population	n.k.	n.k.
Adrenocortical carcinoma	0.7–2.0/ 1.000.000			Median survival: 3–4 years, 5-year survival 60–80% for localized tumors, and 10–20% for metastatic disease



MALATTIA DI ADDISON

Insufficienza surrenalica primitiva





INQUADRAMENTO CLINICO





Table 2. Major Etiologies of PAI and Associated Features

Etiology	Associated Features
Autoimmune	
Isolated	Not associated with other autoimmune disorders
APS type 1 (APECED)	Chronic cutaneous candidiasis, hypoparathyroidism
APS type 2	Autoimmune thyroid disease, type 1 diabetes
Adrenal—infiltration/injury	
Adrenal hemorrhage	Associated with sepsis, anticoagulants, anti-cardiolipin/lupus anti-coagulant syndrome
Adrenal metastases	Malignancies: lung, breast, colon, melanoma, lymphoma
Infections: adrenalitis	Tuberculosis, HIV/AIDS, CMV, candidiasis, histoplasmosis, syphilis, African trypanosomiasis, paracoccidioidomycosis (eg, in South America)
Infiltration	Hemochromatosis, primary amyloidosis
Bilateral adrenalectomy	Procedure for intractable Cushing's syndrome or bilateral pheochromocytoma
CAH: most forms can cause salt loss	Commonest cause of PAI in children (80%); may be diagnosed in older individuals
21-Hydroxylase deficiency	Commonest type of CAH is 21-hydroxylase deficiency, with associated hyperandrogenism
11 β -hydroxylase deficiency	Hyperandrogenism, hypertension (in older children and adults)
3 β -hydroxysteroid dehydrogenase II deficiency	Ambiguous genitalia in boys, hyperandrogenism in girls
P450 side-chain cleavage deficiency (CYP11A1 mutations)	XY sex reversal
P450 oxidoreductase deficiency	Skeletal malformations, abnormal genitalia
Congenital lipoid adrenal hyperplasia (StAR mutations)	XY sex reversal
Adrenal hypoplasia congenita	X-linked NROB1, Xp21 deletion (with Duchenne's muscular deficiency), SF-1 mutations (XY sex reversal), IMAGE syndrome
ACTH insensitivity syndromes	Type 1: ACTH receptor, melanocortin 2 receptor gene MC2R Type 2: MRAP Familial glucocorticoid deficiency (MCM4, NNT, TXNRD2)
Drug-induced	TripleA (Allgrove's) syndrome, achalasia, Addison's disease, alacrima, AAAS gene mutation Adrenal enzyme inhibitors: mitotane, ketoconazole, metyrapone, etomidate, aminoglutethimide, drugs that may accelerate cortisol metabolism and induce adrenal insufficiency T_4 also accelerates cortisol metabolism (at least in part through stimulation of 11 β -HSD2) CTLA-4 inhibitors may enhance autoimmunity and cause PAI
Other metabolic disorders	Mitochondrial disease (rare) Adrenoleukodystrophy in males Wolman's disease



INQUADRAMENTO CLINICO




Etiology	Associated Features
Autoimmune Isolated APS type 1 (APECED) APS type 2	Not associated with other autoimmune disorders Chronic cutaneous candidiasis, hypoparathyroidism Autoimmune thyroid disease, type 1 diabetes

Anticorpi contro la corteccia surrenalica (ACA)

Anticorpi contro l'enzima 21-idrossilasi (21-OHAbs)

90% dei pazienti

presenti alla diagnosi ma anche molti anni prima
predittivi di sviluppo di malattia di Addison



J Clin Endocrinol Metab, February 2016, 101(2):364–389


Betterle et al. In Arvat E, Falorni A (eds): Cortisol Excess and Insufficiency
Front Horm Res. Basel, Karger, 2016, vol 46, pp 133–145 (DOI: 10.1159/000443872)

EFE 2019






INQUADRAMENTO CLINICO




Fattori predittivi di progressione verso la disfunzione surrenalica in pazienti con ACA/21-OH-Ab-positivi

- 1) genere maschile
- 2) tipo di malattia autoimmune associata
(ipoparatiroidismo, candidiasi mucocutanea vs. tireopatia autoimmune o DM1)
- 3) titolo ACA/21-OH-Ab
- 4) livello di funzione surrenalica






INQUADRAMENTO CLINICO




Associazione con APS1



Betterle et al. In Arvat E, Falorni A (eds): Cortisol Excess and Insufficiency
Front Horm Res. Basel, Karger, 2016, vol 46, pp 133–145 (DOI: 10.1159/000443872)




INQUADRAMENTO CLINICO



	APS-1	APS-2
Manifestations		
Endocrine	PAI	PAI
	Hypoparathyroidism	Autoimmune thyroid disease
	Ovarian failure	Type 1 diabetes mellitus
	Type 1 diabetes	
	Autoimmune thyroid disease	
Gastrointestinal	Autoimmune gastritis /pernicious anaemia	Autoimmune gastritis/ pernicious anaemia
	Autoimmune hepatitis	Coeliac disease
	Intestinal malabsorption	
Ectodermal manifestations	Alopecia	Alopecia
	Vitiligo	Vitiligo
	Enamel dysplasia	
	Keratoconjunctivitis	
Hematological	Asplenia	
Others	Chronic mucocutaneous candidiasis	



INQUADRAMENTO CLINICO




Stadi della malattia di Addison

	Stadio	ACA e/o 21-OHAbs	Renina basale	Aldosterone basale	ACTH basale	Cortisolo basale	Cortisolo +60' post ACTH	Clinica
Potenziale	0	+	N	N	N	N	N	No
Subclinico (deficit mineralcorticoidi)	1	+	↑	N	N	N	N	No
Subclinico (deficit mineralcorticoidi + ridotta riserva glucocorticoidi)	2	+	↑	N/↓	N	N	↓	No
Subclinico (deficit mineralcorticoidi e glucocorticoidi)	3	+	↑	↓	↑	N/↓	↓↓	No
Cinico (grave deficit mineralcorticoidi e glucocorticoidi)	4	+	↑↑	↓	↑↑	↓↓	↓↓	Si


Betterle et al. In Arvat E, Falorni A (eds): Cortisol Excess and Insufficiency
Front Horm Res. Basel, Karger, 2016, vol 46, pp 133–145 (DOI: 10.1159/000443872)



INQUADRAMENTO CLINICO




Fasi della malattia di Addison



Betterle et al. In Arvat E, Falorni A (eds): Cortisol Excess and Insufficiency
 Front Horm Res. Basel, Karger, 2016, vol 46, pp 133–145 (DOI: 10.1159/000443872)



INQUADRAMENTO CLINICO



MALATTIA DI ADDISON

Insufficienza surrenalica primitiva






Table 2. Major Etiologies of PAI and Associated Features

Etiology	Associated Features
Adrenal infiltration/injury	
Adrenal hemorrhage	Associated with sepsis, anticoagulants, anti-cardiolipin/lupus anti-coagulant syndrome
Adrenal metastases	Malignancies: lung, breast, colon, melanoma, lymphoma
Infections: adrenalitis	Tuberculosis, HIV/AIDS, CMV, candidiasis, histoplasmosis, syphilis, African trypanosomiasis, paracoccidioidomycosis (eg, in South America)
Infiltration	Hemochromatosis, primary amyloidosis
Bilateral adrenalectomy	Procedure for intractable Cushing's syndrome or bilateral pheochromocytoma



MALATTIA DI ADDISON


Insufficienza surrenalica primitiva



Sindrome di Waterhouse Friederichsen


insufficienza surrenalica acuta emorragica correlata a setticemia

(Neisseria meningitidis, Pseudomonas aeruginosa, Hemophilus influenzae, Streptococchi)



MALATTIA DI ADDISON

Insufficienza surrenalica primitiva





INQUADRAMENTO CLINICO






Table 2. Major Etiologies of PAI and Associated Features

Etiology	Associated Features
CAH: most forms can cause salt loss	Commonest cause of PAI in children (80%); may be diagnosed in older individuals
21-Hydroxylase deficiency	Commonest type of CAH is 21-hydroxylase deficiency, with associated hyperandrogenism
11 β -hydroxylase deficiency	Hyperandrogenism, hypertension (in older children and adults)
3 β -hydroxysteroid dehydrogenase II deficiency	Ambiguous genitalia in boys, hyperandrogenism in girls
P450 side-chain cleavage deficiency (CYP11A1 mutations)	XY sex reversal
P450 oxidoreductase deficiency	Skeletal malformations, abnormal genitalia
Congenital lipoid adrenal hyperplasia (StAR mutations)	XY sex reversal


La forma più frequente è il deficit di 21-idrossilasi






MALATTIA DI ADDISON

Insufficienza surrenalica primitiva





INQUADRAMENTO CLINICO



Anticoagulanti



Emorragia surrenalica

Ketoconazolo
Mitotane
Rifampicina
Abiraterone
Carbamazepina
Etomidate
Fenitoina
Inquinanti ambientali



Alterazione della sintesi o del
metabolismo dei glucocorticoidi

Immune checkpoint
inhibitors



Adrenalite autoimmune



Bornstein SR. Predisposing factors for adrenal insufficiency. *N Engl J Med* 2009; 360: 2328–2339

Konda et al. *Curr Opin Endocrinol Diabetes Obes* 2017; 24: 337–347


Barroso-Sousa et al. *JAMA Oncol* 2018; 4: 173–182

EFE 2019





INQUADRAMENTO CLINICO



MANIFESTAZIONI CLINICHE

Segni ipocorticosurrenalismo

*M. di Addison:
iperpigmentazione
e delle gengive,
mucose, capelli
scuri, lentiggini*



vitiligine

Iperpigmentazione aree di attrito e capezzoli

Iperpigmentazione solchi cutanei




Febbre

Dimagrita,
abbronzata...
Sei appena tornata
dalle vacanze?



No, ho il
Morbo di Addison!

e
ia
le
nerale
n giustificata



MANIFESTAZIONI CLINICHE

Segni ipocorticosurrenalismo




Ipoglicemia
Iperkaliemia
Iponatraemia
Deplezione di volume

Attenzione a pazienti con patologie autoimmuni (vitiligine, diabete mellito di tipo 1, gastrite autoimmune) o con malattie infettive (TBC, HIV, citomegalovirus, candidiasi, istoplasmosi)



INQUADRAMENTO CLINICO



MANIFESTAZIONI CLINICHE

SPECIAL FEATURE

Clinical Practice Guideline

Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline

Symptoms

Adrenal insufficiency

Fatigue

Weight loss
Postural dizziness

Anorexia, abdominal discomfort

Adrenal crisis

Severe weakness
Syncope
Abdominal pain, nausea, vomiting;
may mimic acute abdomen
Back pain
Confusion

Signs

Hyperpigmentation (primary only), particularly of sun-exposed areas, skin creases, mucosal membranes, scars, areola of breast
Low blood pressure with increased postural drop
Failure to thrive in children

Hypotension
Abdominal tenderness/guarding
Reduced consciousness, delirium


Routine Laboratory Tests

Hyponatremia
Hyperkalemia
Uncommon: hypoglycemia, hypercalcemia
Hyponatremia
Hyperkalemia
Hypoglycemia
Hypercalcemia






INQUADRAMENTO CLINICO



MANIFESTAZIONI CLINICHE


Insufficienza surrenalica acuta

EMERGENZA ENDOCRINA






INQUADRAMENTO CLINICO



MANIFESTAZIONI CLINICHE

Insufficienza surrenalica acuta

EMERGENZA ENDOCRINA






MALATTIA DI ADDISON





INQUADRAMENTO CLINICO





INQUADRAMENTO CLINICO



Grazie per l'attenzione